KPW
MRTX

Kore Private Wealth’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Kore Private Wealth’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-655
Closed -$74K – 1139
2020
Q2 		$74K Hold
655
– – 0.02% 384
2020
Q1 		$50K Buy
655
+52
+9% +$4.66K 0.01% 418
2019
Q4 		$78K Buy
+603
New +$58.2K 0.01% 411
2019
Q2 		– Sell
-250
Closed -$18K – 818
2019
Q1 		$18K Hold
250
– – ﹤0.01% 523
2018
Q4 		$11K Buy
+250
New +$9.96K ﹤0.01% 565

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Kore Private Wealth's MRTX Position: Q3 2020 in Review

Kore Private Wealth sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2020, closing a stake of 655 shares — an estimated $74K sold.

Kore Private Wealth first reported a position in MRTX in Q4 2018 and held it in 5 quarters. The position peaked at $78K in Q4 2019. 225 funds tracked by Wall St. Rank hold MRTX as of Q3 2020.

  • Kore Private Wealth reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Kore Private Wealth sold 655 Mirati Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $74K.
  • Kore Private Wealth first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2018 and held it in 5 quarters.
  • Kore Private Wealth's Mirati Therapeutics, Inc. Common Stock position peaked at $78K in Q4 2019.
  • 225 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.